Pulmonology
Conference Coverage
Metapneumovirus infections clinically indistinguishable from flu, RSV
Conference Coverage
VTEs tied to immune checkpoint inhibitor cancer treatment
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...
Conference Coverage
FDA-approved peanut immunotherapy protocol comes with a cost
Most allergists are not interested in developing home-grown treatments because it comes with legal risks.
Conference Coverage
Poverty raises depression risk in patients with cystic fibrosis
Adherence barriers and suboptimal adherence are issues that cross all socioeconomic categories, though they were more problematic in the lowest...
From the Journals
Dripping, dabbing, and bongs: Can’t tell the players without a scorecard
These alternate aerosol inhalation methods have been poorly described thus far.
Conference Coverage
Triple combination therapy for cystic fibrosis linked to plunging hospitalizations
Cystic fibrosis hospitalizations reduced to zero at a center in Oregon, but the COVID-19 pandemic may be a factor.
Conference Coverage
Cystic fibrosis patients’ vulnerability to COVID-19 infection: Preliminary data ease fears
Analyses of U.S. and international registries suggest risks are in line with the general population.
Conference Coverage
Pregnancy can be safe with interstitial lung disease
Often women with ILD related to an autoimmune disease are advised to avoid conception or terminate their pregnancies. But the largest study to...
Med Tech Report
Medication adherence challenges and helpers
Thankfully, there are tools designed to help remind patients of what they need to take and when.
Conference Coverage
Home spirometry improved monitoring of cystic fibrosis patients during COVID-19 pandemic
Home spirometry values were slightly lower than clinic values, but reliably picked up changes from baseline.
Conference Coverage
Cystic fibrosis treatment: Triple combination benefits patients with advanced disease
The researchers conducted an open-label retrospective analysis of 60 patients started on triple combination therapy.